PITTSFORD, NY--(Marketwire - April 23, 2008) - Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that its board of directors approved the next phase of Myotech's engineering and regulatory development program for the Myotech CSS. The Biophan board met following a Myotech board of directors' vote, agreed on implementing this strategic initiative, and released $2 million for the next phase of engineering and regulatory work towards commercialization. Myotech is a majority owned subsidiary of Biophan.
